ADARx Pharmaceuticals, A Leader in Next Generation RNA Therapeutics, Announces Oversubscribed $200 M
Proceeds to Further Advance Company’s Lead Clinical ProgramsSAN DIEGO--(BUSINESS WIRE)--ADARx Pharmaceuticals, Inc. (“ADARx” or “the Company”), a clinical stage biotechnology company developing next generation RNA therapeutics, today announced the successful close of an oversubscribed $200 million Series C financing...